The company clocked a 4% increase in net profit, which stood at ₹4.53 crore for Q2 of the ongoing financial year. This ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Drug firm Divi's Laboratories on Monday said its profit after tax (PAT) increased 65 per cent to Rs 589 crore for the ...

In the corresponding quarter of the previous fiscal, Alembic Pharmaceuticals posted a net profit of ₹180.4 crore. The company ...

A significant chunk of revenue for most Indian generic drugmaker comes from the U.S. and fierce competition in the North ...

The stock was last seen trading 5.18 per cent up at Rs 8,415.85. At this price, it has climbed 13.55 per cent in the past one ...

Titan’s revenue from operations in Q3FY25 is estimated to grow 25% YoY, while its net profit is expected to remain flat due ...

Indian drugmaker Alembic Pharmaceuticals reported a lower third-quarter profit on Monday, weighed down by weak local sales of its drugs that treat acute illnesses.

MercadoLibre has robust growth with significant ad revenue gains. See why MELI stock's high P/E ratio is justified, and why ...

India's Divi's Laboratories reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses on customised production of chemical compounds used in ...

Despite Reddit's strong fundamentals and network effects, valuation appears 50% too high. Learn why RDDT stock is a Sell.

For three quarters running, Alphabet (Nasdaq: GOOG) (Nasdaq: GOOGL) has surprised and delighted its shareholders with ...